First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
Solid Tumors|Sarcoma
DRUG: DS-2243a
Part 1: Number of participants with Dose-Limiting Toxicities at each dose level of DS-2243a, Up to 18 months|Part 2: Number of participants with Treatment-Emergent Adverse Events, Descriptive statistics of treatment-emergent adverse events (TEAEs), Up to 3 years|Part 2: Objective Response Rate, Objective Response Rate (ORR) as assessed by the investigator according to RECIST v1.1., From day of first dose up to 3 years
Part 1: Objective Response Rate, ORR as assessed by the investigator according to RECIST v1.1., From day of first dose up to 3 years|Disease Control Rate, Disease Control Rate (DCR) as assessed by the investigator according to RECIST v1.1., From day of first dose up to 4 years.|Progression-Free Survival (PFS), Progression-Free Survival (PFS) as assessed by the investigator according to RECIST v1.1., From day of first dose up to 4 years|Overall Survival, From day of first dose up to 4 years|Drug Plasma Concentration, Days 1, 2, and 3 during step-up dosing; Days 1, 2, 3, 5, 8, and 15 of Cycles 1 and 3; Day 1 of Cycle 2; and Day 1 of Cycle 4 and each subsequent cycle. A cycle is 21-days.
This is a global, multicenter, open-label, first-in-human, Phase 1 trial of DS-2243a as a treatment for locally advanced or metastatic synovial sarcoma (SS), myxoid/round cell liposarcoma (MRCLS), squamous cell carcinoma type non-small cell lung cancer (Sq-NSCLC), adenocarcinoma type non-small cell lung cancer (Ad-NSCLC), or urothelial carcinoma (UC) participants with HLA-A2 and/or NY-ESO positive. The trial consists of 2 parts: the Dose Escalation Part (Part 1) and the Dose Expansion Part (Part 2).